New patent for Abbvie drug NAMZARIC

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Annual Drug Patent Expirations for NAMZARIC
Annual Drug Patent Expirations for NAMZARIC

Namzaric is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and three Paragraph IV challenges.

NAMZARIC drug price trends.

Drug patent litigation for NAMZARIC.

This drug has fifty-five patent family members in eighteen countries.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. One supplier is listed for this compound. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions
Scroll to Top